Alector Shares Up, Focus Turns to Pipeline After Setback
Alector shares rose 3.7% to $2.27 late Wednesday morning on the Nasdaq, outperforming a 1.2% gain in the XBI biotech ETF. The move follows last month’s halt of its GSK-partnered Alzheimer’s trial for futility and comes as investors weigh its early-stage brain-delivery platform against ongoing cash burn and a new $125 million stock sale program.
